EP-1160 Increasing radiotherapy responsiveness of mesothelioma by activating tumour specific cell death  by Dayal, S. et al.
3rd ESTRO Forum 2015                                                                                                                                         S631 
 
EP-1160   
Increasing radiotherapy responsiveness of mesothelioma 
by activating tumour specific cell death 
 
S. Dayal1, M. Verheij2, A. Chalmers3 
1Institute of Cancer Sciences, WWCRC Building, Glasgow, 
United Kingdom  
2Netherlands Cancer Institute, Department of Radiotherapy, 
Amsterdam, The Netherlands  
3West of Scotland Cancer Centre, Clinical Oncology Gartnavel 
General Hospital, Glasgow, United Kingdom  
 
Purpose/Objective: Mesothelioma is a radioresistant cancer 
and around 80% of the cases occur due to asbestos exposure. 
The incidence of mesothelioma is increasing and current 
treatments are ineffective. While advances in technical 
radiotherapy are increasing its potential clinical application, 
the intrinsic radiation resistance of mesothelioma remains an 
important barrier. Defects in the apoptosis pathway are a 
likely cause of radioresistance and treatment with Tumour 
necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) has 
potential to overcome this. 
Materials and Methods: Radiation and TRAIL (iso-leucine 
zippered form) were tested alone and in combination in 
mesothelioma cell lines MSTO-211H and H2052 to determine 
effects on cell viability, clonogenic survival and apoptosis 
(measured by caspase-3/7 activity and Annexin-V/PI 
analysis). Cell surface and total levels of the death receptors 
DR4 and DR5 were also analysed to investigate potential 
mechanisms underlying interactions between radiation and 
TRAIL.  
Results: Radiation and TRAIL exhibit schedule-dependent 
synergy. Addition of TRAIL 24 hours post radiation was 
associated with significant increases in apoptosis and 
reductions in cell viability and clonogenic survival in both cell 
lines. Radiation caused upregulation and externalisation of 
DR4 & DR5 with maximum effects 24 hours after radiation. 
We hypothesised that radiation induces DR4/5 upregulation 
and externalisation enabling activation of the extrinsic 
apoptotic pathway by TRAIL. This was verified by showing 
that inhibition of the extrinsic apoptotic pathway blocked the 
cytotoxic effects of the radiation/TRAIL combination whereas 
inhibition of the intrinsic pathway did not. 
Conclusions: Use of TRAIL in combination with radiation 
overcomes radioresistance exhibited by mesothelioma cells. 
The synergistic combination of TRAIL and radiation has 
therapeutic potential in mesothelioma. 
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Purpose/Objective: FDG PET/CT has become a routine 
diagnostic instrument for staging and treatment planning of 
NSCLC. There is an increasing interest in quantitative 
metabolic evaluation of FDG PET as an early marker of 
response during and shortly after treatment. Routine 
diagnostic FDG PET/CT scans that were performed for staging 
purposes are often used at baseline for standardized uptake 
value (SUV) measurements. However, a diagnostic scan may 
be suboptimal for this purpose for several reasons, e.g. it 
may be relatively old, not in treatment position, or acquired 
with equipment with different characteristics compared to 
the one used for response evaluation. We hypothesized that a 
separate baseline FDG PET/CT at the start of treatment may 
provide more reliable response monitoring. 
Materials and Methods: We included 13 patients with proven 
NSCLC, who were referred for curative intent concurrent 
chemoradiation (CCRT) in an ongoing prospective trial for 
quantitative evaluation of tumor metabolism during 
treatment. All patients had already received a routine FDG 
PET/CT in the diagnostic work-up (PET1), and underwent a 
2nd scan in the morning prior to fraction 1 (PET2). Noted were 
the interval between PET1 and start of treatment, FDG 
biodistribution time, SUVmax of the primary tumor, and 
whether PET1 was performed in a different center or with a 
different scanner brand than PET2. All applied scanners were 
calibrated for SUV measurements using standard quality 
assurance procedures. 
Results: Significant time intervals with mean 38 days (range 
20-60) occurred between PET1 and start of treatment (PET2). 
FDG biodistribution times were comparable with mean 68 
minutes for both PET1 and PET2, although deviations were 
slightly larger for PET1 (range 53-107 minutes, versus 54-91 
for PET2). SUVmax values showed large differences between 
PET1 and PET2 (absolute mean +29%, range -35-+84%). None 
of the PET1 scans were performed in treatment position. The 
patients who had both scans acquired on the same scanner 
brand (Philips TF) generally showed SUVmax progression before 
the start of treatment (mean +33%, range -11-+84%), 
consistent with assumed variable tumor progression. 
However, most patients with a baseline scan acquired using a 
different scanner brand (all Siemens) showed a lower SUVmax 
at the start of treatment (mean -14%, range -34-+10), 
indicating a significant quantification issue despite all 
scanners being calibrated for SUV. One patient showed 
progression to stage IV on PET2 (with an interval of 48 days 
with PET1), leading to change of management. 
Conclusions: SUV quantification using a routine staging FDG 
PET/CT may deviate significantly from measurements at the 
start of treatment, with differences up to 84% that were 
apparently caused by tumor progression, positioning 
differences and application of different scanner brands. A 
baseline PET shortly before treatment on the same scanner 
brand is recommended for quantitative monitoring of 
metabolic parameters during (chemo)radiotherapy for NSCLC 
to avoid misinterpretation of signal changes.  
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